Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

Rongqing Pan, Vivian R. Ruvolo, Jun Wei, Marina Konopleva, John C. Reed, Maurizio Pellecchia, Michael Andreeff, Peter P. Ruvolo

Blood (2015) 126 (3): 363–372.

https://doi.org/10.1182/blood-2014-10-604975

Published: 2015

Includes: Supplemental data

Journal Articles

Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib

Heather S. Leu, B.S., Daniel J Goff, PhD, Janine Low-Marchelli, PhD, Angela C Court Recart, BS, MS, Kristen M. Smith, Ph.D., Wenxue Ma, M.D., Ph.D., Anil Sadarangani, Ph.D., Alice Y. Shih, B.S., Jun Wei, Ph.D., Dayong Zhai, Ph.D., Jason Gotlib, M.D., M.S., Mark D. Minden, MD, PhD, Giovanni Martinelli, MD, Marco A. Marra, PhD, Kelly A Frazer, Ph.D., Maurizio Pellecchia, PhD, John C. Reed, MD, PhD, Catriona Jamieson, MD, PhD

Blood (2012) 120 (21): 3739.

https://doi.org/10.1182/blood.V120.21.3739.3739

Published: 2012

Journal Articles

Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2–transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)

Shinichi Kitada, Christina L. Kress, Maryla Krajewska, Lee Jia, Maurizio Pellecchia, John C. Reed

Blood (2008) 111 (6): 3211–3219.

https://doi.org/10.1182/blood-2007-09-113647

Published: 2008

Includes: Supplemental data

Journal Articles

Bcl-2 Antagonist ApoGossypol (NSC736630) Displays Single-Agent Activity in Bcl-2 Transgenic Mice and Has Superior Efficacy and Pharmacology with Less Toxicity Compared to Gossypol (NSC19048).

Shinichi Kitada, MD, PhD, Lee Jia, Ph.D., Lori C. Coward, Ph.D., Greg S. Gorman, Ph.D., Patricia Noker, Ph.D., Maurizio Pellecchia, Ph.D., John C. Reed, M.D., Ph.D.

Blood (2006) 108 (11): 2487.

https://doi.org/10.1182/blood.V108.11.2487.2487

Published: 2006

Journal Articles

Apoptosis-based therapies for hematologic malignancies

John C. Reed, Maurizio Pellecchia

Blood (2005) 106 (2): 408–418.

https://doi.org/10.1182/blood-2004-07-2761

Published: 2005

NARROW

Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib

Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2–transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)

Bcl-2 Antagonist ApoGossypol (NSC736630) Displays Single-Agent Activity in Bcl-2 Transgenic Mice and Has Superior Efficacy and Pharmacology with Less Toxicity Compared to Gossypol (NSC19048).

Apoptosis-based therapies for hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia

Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib

Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2–transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)

Bcl-2 Antagonist ApoGossypol (NSC736630) Displays Single-Agent Activity in Bcl-2 Transgenic Mice and Has Superior Efficacy and Pharmacology with Less Toxicity Compared to Gossypol (NSC19048).

Apoptosis-based therapies for hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only